Results 51 to 60 of about 818 (145)

Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research

BioMed Research International, Volume 2013, Issue 1, 2013., 2013
There is no malaria vaccine currently available, and the most advanced candidate has recently reported a modest 30% efficacy against clinical malaria. Although many efforts have been dedicated to achieve this goal, the research was mainly directed to identify antigenic targets.
Elena Mata, Aiala Salvador, Manoli Igartua, Rosa María Hernández, José Luis Pedraz, Udai P. Singh   +5 more
wiley   +1 more source

Development of a rapid in vitro pre-screen for distinguishing effective liposome-adjuvant delivery systems

Scientific Reports, 2022
Liposomes are a strong supporting tool in vaccine technology, as they are a versatile system that not only act as antigen delivery systems but also adjuvants that can be highly effective at stimulating both innate and adaptive immune responses.
Laura A. J. Feather, Vinod Nadella, Elisabeth Kastner, Yvonne Perrie, Anthony C. Hilton, Andrew Devitt   +5 more
doaj   +1 more source

Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves.

PLoS ONE, 2018
There is a need for the rational design of safe and effective vaccines to protect against chronic bacterial pathogens such as Mycobacterium tuberculosis and Mycobacterium avium subsp. paratuberculosis in a number of species.
Aneesh Thakur, Athina Andrea, Heidi Mikkelsen, Joshua S Woodworth, Peter Andersen, Gregers Jungersen, Claus Aagaard   +6 more
doaj   +1 more source

Mycobacterium bovis Bacille Calmette‐Guérin as a Vaccine Vector for Global Infectious Disease Control

Tuberculosis Research and Treatment, Volume 2011, Issue 1, 2011., 2011
Mycobacterium bovis bacille Calmette‐Guérin (BCG) is the only available vaccine for tuberculosis (TB). Although this vaccine is effective in controlling infantile TB, BCG‐induced protective effects against pulmonary diseases in adults have not been clearly demonstrated.
Kazuhiro Matsuo, Yasuhiro Yasutomi, Brian Eley   +2 more
wiley   +1 more source

CAF01 induction of cellular immunity.

, 2014
A and B. Mice were vaccinated twice at two weeks intervals with IPV (TP) 2DU (white bars), IPV 20DU (grey bars) or IPV 2DU + CAF01 (black bars). Striped bars indicate non-vaccinated mice.
Else Marie Agger (104700), Peter Andersen (88335), Lars Vibe Andreasen (582339), Jes Dietrich (154335)   +3 more
core   +1 more source

Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T‐cell responses and anti‐tumor immunity by targeting conventional type 1 dendritic cells

Immunology &Cell Biology, Volume 103, Issue 9, Page 825-843, October 2025.
Therapeutic cancer vaccines require CD8+ T‐cell activation for efficacy. This response can be enhanced by rationally designing polymeric nanoparticle adjuvants. The importance of antigen location for the adjuvanticity of polymeric nanoparticles has not been fully resolved.
Jorge Huete‐Carrasco, Jingjing Zhu, Benoit J Van den Eynde, Christian Thomas Mayer, Tim Sparwasser, Ross W Ward, Ed C Lavelle   +6 more
wiley   +1 more source

Monocytes Elicit a Neutrophil-Independent Th1/Th17 Response Upon Immunization With a Mincle-Dependent Glycolipid Adjuvant

Frontiers in Immunology, 2022
Successful subunit vaccination with recombinant proteins requires adjuvants. The glycolipid trehalose-dibehenate (TDB), a synthetic analog of the mycobacterial cord factor, potently induces Th1 and Th17 immune responses and is a candidate adjuvant for ...
Christiane Desel, Peter J. Murray, Peter J. Murray, Christian H. K. Lehmann, Lukas Heger, Dennis Christensen, Peter Andersen, Matthias Mack, Diana Dudziak, Roland Lang   +9 more
doaj   +1 more source

CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

, 2010
Mucosal administration of vaccines has many advantages compared to parenteral vaccination. Needle-free mucosal vaccination would be easily applicable, target the vaccine to the entry point of many pathogens, and reduce the risk of infection with other ...
Andersen, Peter, Christensen, Dennis, Lundberg, Carina Vingsbo, Rosenkrands, Ida, Agger, Else Marie, Nielsen, Hanne Mørck, Foged, Camilla   +6 more
core   +1 more source

Intranasal administration of unadjuvanted SARS‐CoV‐2 spike antigen boosts antigen‐specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters

European Journal of Immunology, Volume 54, Issue 6, June 2024.
Intranasal administration of spike protein antigen alone following an intramuscular prime with spike protein antigen adjuvanted with sulfated lactosylarchaeol (SLA) archaeosomes boosts systemic and mucosal immune responses, leading to protection from SARS‐CoV‐2 infection.
Gerard Agbayani, Bassel Akache, Tyler M. Renner, Anh Tran, Matthew Stuible, Renu Dudani, Blair A. Harrison, Diana Duque, Jegarubee Bavananthasivam, Lise Deschatelets, Usha D. Hemraz, Sophie Régnier, Yves Durocher, Michael J. McCluskie   +13 more
wiley   +1 more source

Genital Infiltrations of CD4+ and CD8+ T Lymphocytes, IgA+ and IgG+ Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydiatrachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01

Frontiers in Microbiology, 2019
The development of a vaccine against genital chlamydia in women is advancing, and the evaluation of in situ immune responses following vaccination and challenge infections is crucial for development of a safe and protective vaccine.
Karin Erneholm, Karin Erneholm, Emma Lorenzen, Emma Lorenzen, Sarah Bøje, Sarah Bøje, Anja Weinreich Olsen, Gregers Jungersen, Henrik E. Jensen, Joseph P. Cassidy, Peter Andersen, Jørgen S. Agerholm, Frank Follmann   +12 more
doaj   +1 more source